ActoGeniX reports positive results from Phase I trial of AG014 to treat inflammatory bowel disease
The results show that AG014 is safe and well tolerated while providing localized gastro-intestinal (GI) exposure. AG014 is the company’s ActoBiotics delivery platform and works by expressing and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.